GSK plc (NYSE:GSK) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. lessened its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 10.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 127,651 shares of the pharmaceutical company's stock after selling 14,697 shares during the period. Advisors Asset Management Inc.'s holdings in GSK were worth $4,317,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Indiana Trust & Investment Management Co grew its stake in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new position in GSK during the fourth quarter worth about $26,000. ST Germain D J Co. Inc. increased its holdings in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 522 shares in the last quarter. Sunbelt Securities Inc. lifted its position in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after acquiring an additional 302 shares during the period. Finally, Sierra Ocean LLC purchased a new stake in shares of GSK during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GSK. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.25.

Remove Ads

GSK Price Performance

GSK stock traded up $0.08 during mid-day trading on Tuesday, hitting $38.65. 5,835,428 shares of the company were exchanged, compared to its average volume of 4,962,484. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.92. The company has a market capitalization of $80.00 billion, a P/E ratio of 24.31, a PEG ratio of 1.12 and a beta of 0.58. The business's 50 day simple moving average is $36.77 and its two-hundred day simple moving average is $36.84. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.07%. The ex-dividend date is Friday, February 21st. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is currently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.